The Intersection of Geriatric and Forensic Psychiatry

Oct 30, 2015

This article reviews a wide array of medicolegal, risk management, regulatory, and forensic mental health issues in the older population, which is growing at an accelerated rate.

The older population in the US is growing at an accelerated rate, which is due, in part, to aging baby boomers. It is estimated that by 2050, the population of those age 65 and older will reach approximately 83.7 million people, almost double that of 43.1 million in 2012.1 In parallel with this population growth, a wide array of medicolegal, risk management, regulatory, and forensic mental health issues will take on increasing importance, some having particular significance in the elderly population. This article reviews some of the many important topics at the intersection of geriatric and forensic psychiatry.

Neuropsychiatric assessment

[[{"type":"media","view_mode":"media_crop","fid":"42453","attributes":{"alt":"© Alexander Raths/shutterstock.com","class":"media-image media-image-right","id":"media_crop_263394932858","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"4599","media_crop_rotate":"0","media_crop_scale_h":"117","media_crop_scale_w":"150","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"float: right;","title":"© Aleksei Potov/shutterstock.com","typeof":"foaf:Image"}}]]The clinical assessment is usually linked to forensic issues or questions. In relation to cases involving the elderly, several factors that may have an impact on thinking, mood, behavior, and cognition need to be considered. Comorbid medical and neurological conditions, polypharmacy, problems with sensory input, and focal cognitive deficits can all affect the mental state examination and need to be taken into consideration. A review of collateral psychiatric, medical, and neurological records is also a critical part of a thorough assessment.

Medical and neurological examinations, laboratory evaluation, brain imaging, and neuropsychological testing may all provide essential information linked to the forensic question. For example, in an elderly patient with cognitive impairment who is being assessed for decision-making ability, differentiating focal deficits from global impairment and progressive cognitive deterioration from reversible deficits may be central to issues that involve different forms of capacity and competency, safety, and advanced planning.

Capacity to make informed treatment decisions

Assessment of an elderly patient’s ability to make informed decisions about his or her health care usually involves a process of evaluation over a period of time. One model of the assessment of capacity involves the examination of 4 functional areas2:

• The ability to communicate a stable choice

• The ability to understand relevant factual information within the context of the treatment decision

• The ability to appreciate how the situation and outcome affect one’s personal life

• The ability to weigh the risks and benefits of options in the process of making a decision

The informed consent process requires additional measures after the determination of capacity. Questions about a patient’s ability to make decisions regarding evaluations and treatment can arise in various situations, including acute medical and surgical settings, psychiatric settings, with a primary care physician, and at nursing and assisted-living facilities. Of particular importance in the elderly population, capacity related to decisions about treatment and other types of capacity may be fluid and subject to change over time. Variables such as age, educational level, and cognition are significant to the assessment; in particular, there is a correlation between cognitive state and degree of deficits and capacity to make decisions about treatment.3,4

Results from a study that compared cognitive screening instruments in relation to capacity to make informed treatment decisions showed that a test of executive functioning was superior to a global cognitive screen.5 A thorough assessment of an elderly patient’s ability regarding medical decision making involves a multifaceted approach, including repeat assessments, education to teach a patient factual information about which decisions need to be made, and consideration of variables such as cognition, medical comorbidity, current medications, visual and auditory sensory deficits, educational background, and psychiatric state.

The potential risks and benefits of a procedure or treatment also need to be factored into the assessment, because this will relate to the appropriate threshold for capacity. For example, a complete blood cell count may be low risk and high benefit, compared with a novel treatment with high risk and limited benefit-the latter scenario requires a higher threshold of decision-making capacity.

Informed consent

A patient’s ability to give informed consent is based on 3 supporting concepts: information, voluntariness, and capacity.6 Analogous to a tripod, all 3 of these components need to be present in order for a patient to meaningfully give consent in the clinical setting. In the elderly patient, it is particularly relevant to examine each of these components. In addition, the concept of voluntariness needs to be considered, given concerns for vulnerability in the elderly to excessive or inappropriate influences from others, including family and friends. One important aspect to this process is communication between physician and patient, in a shared decision-making framework, in which the physician can confirm patient comprehension and take into account factors that may impede comprehension, including coexisting disabilities (eg, cognitive, visual), level of education, and personality.7

A study that examined capacity to consent to research in the elderly assessed comprehension, quality of reasoning, and making a reasonable choice.8 Elderly patients did not differ from younger patients in making a reasonable choice but had poorer comprehension ability. The results of this study stress the importance of screening for competency and providing additional instructions in elderly patients.

The Comprehensive Geriatric Assessment is an instrument that can assist in the informed consent evaluation process.9 It measures capacities such as functional state, cognitive status, social support, and advance care preferences.

Testamentary capacity

Testamentary capacity refers to the advanced planning ability to make or change a will, an estate plan, or decisions about finances; it is similar in concept to other types of capacity or competency. Assessment can include the same framework of functional areas or standards described above for capacity to make treatment decisions, but the focus is specifically on the person’s (testator’s) knowledge of the extent and value of his or her property, who the natural heirs are, and how the distribution is being applied. A challenge to testamentary capacity usually comes when a relative or heir feels he or she did not receive what was deserved. The significance of the concept of testamentary capacity is based on societal need to protect vulnerable older people from abuse.10

Related to testamentary capacity is the issue of undue influence, whereby a person or system exerts authority over a vulnerable individual, which may then affect that person’s decision making regarding property and finances. Numerous risk factors have been described, which may help in the risk assessment for undue influence and vulnerability, including dependency, isolation, physical disability, family conflicts, mental disorders, and wills containing provisions that seem inconsistent with the testator’s previous wishes or beliefs.11

Advanced planning and end-of-life decisions

Advanced planning involves decision making and documentation prepared while the patient has intact capacity, which provides for future instructions should the patient become incapacitated and unable to communicate a rational decision. The patient continues to make decisions while clinically judged to have the capacity to do so. Advanced directives include:

• A durable power of attorney, which names someone to make decisions about private, business, and legal issues on a person’s behalf when he or she is incapacitated

• A health care proxy (HCP), which names someone to make health-care related decisions when and if the patient is unable to

The HCP provides instructions regarding life-extending care and resuscitation. An important foundation for end-of-life decision making is that an individual has the right to refuse treatment.

Two legal cases are central to end-of-life decision making. One is the Karen Ann Quinlan case in the mid-1970s, in which the New Jersey Supreme Court ruled that the right to privacy includes a right to refuse medical treatment.12 In a similar case involving Nancy Beth Cruzan in 1990, the US Supreme Court affirmed a patient’s right to refuse medical treatment, including artificial nutrition and hydration.13 Competing interests from the state, including the need to maintain life and prevent suicide, make these decisions complex and necessitate legal and ethical input.14

The standard approach to end-of-life decision making in elderly patients includes families and health care professionals; it involves the assessment and documentation of decision-making capacity and the need to prepare unambiguous written advance directives that identify substitute decision makers. The complexity of this shared decision-making process is highlighted by various ethical issues, such as the amount and type of medical care involving the very elderly and terminally ill, the use of comfort measures and palliative care, and participation in research.

Guardianship

The approach to assessing the need for guardianship in those without advanced planning and directives starts with an evaluation of capacity, determination whether capacity is impaired temporarily or permanently, the causes of any diminished capacity, and what types of decisions or actions a guardian will make. A number of disorders can result in the need for either temporary or permanent guardianship, including delirium, dementia, stroke, traumatic brain injury, neurodevelopmental disorders, and psychoses. Areas in which capacity to make decisions are assessed and for which a guardian may be needed include routine health care, decisions about finances and business, and decisions about medical care that can be state specific and include use of antipsychotic medication and electroconvulsive therapy.

Related to the issue of capacity, an individual may have impaired decision-making ability in one area, yet retain capacity or competency in another area, and the responsibilities of a substitute decision-maker may be focused and context specific. As described above, capacity can fluctuate over time. For example, an impaired individual with a history of poor capacity related to treatment decisions, who is now in good health and lives in a supportive setting, may not have an immediate need for a guardian of person to make treatment decisions. The clinical team, attorneys, and court may take into account the urgency and valence of the need for a substitute decision maker in the guardianship application process.

It is important to note that a person is, in the eyes of society and the courts, competent until adjudicated incompetent, and it is recommended that written authorization be obtained from the person being evaluated. The report documenting the capacity assessment and need for guardianship may be subject to the Health Insurance Portability and Accountability Act of 1996 (HIPAA) Privacy, Security, and Breach Notification Rules in some, but not all, situations. (The US Department of Health and Human Services website or your hospital or private legal office are good sources for specific information.15)

Psychopharmacology and risk management

Concurrent use of multiple medications is common in geriatric patients and carries a heightened risk of adverse outcomes. There are several important considerations related to psychopharmacology and polypharmacy in this population. One issue involves changes in drug metabolism and clearance and body composition as people age. The risk of adverse effects increases as the medication load is increased and clearance is reduced. Four common medications and classes were found to be particularly problematic in the elderly: warfarin, insulin, oral antiplatelet agents, and oral hypoglycemics.16

Pharmacokinetic/pharmacodynamic changes in the elderly increase the risk of drug-drug interactions, including psychotropics.17 Polypharmacy carries the added risk of a prescribing cascade, an adverse drug event that is misinterpreted as a medical symptom or condition and results in a prescription for another drug. Symptoms mistakenly attributed to a medical condition may also result in more testing, which can carry an added risk.18 The following steps are recommended for decreasing medical risk in the elderly:

• Consider new signs and symptoms as a possible result of the patient’s current medications

• Before any new drug treatment is started, the need for the drug should be re­evaluated

• If drug treatment is necessary, the lowest feasible dose of the drug should be used and alternative drugs with fewer adverse effects considered

Another practical issue with polypharmacy is medication adherence and appropriate management. As the number/variety of medications and doses increase, there is an increased risk of missing or mismanaging doses. Several factors play a role in medication management, including cognition, vision and other sensory input, and motivation. Several medication classes are problematic in the elderly and require closer consideration of risks and benefits, including benzodiazepines/sedative-hypnotics and medications with anticholinergic effects.

The updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults can help assess risks/benefits in treatment decision making.19 In addition, recommendations that can lower risk to elderly patients include eliminating unnecessary medications and avoiding a prescribing cascade, monitoring for adverse effects and blood levels, and educating and coordinating with patients, families, and caregivers to ensure safer medication administration.

Disclosures:

Dr Holzer is on staff at the McLean Geriatric Outpatient and Memory Diagnostic Clinic and faculty at Harvard Medical School in Boston. He reports no conflicts of interest concerning the subject matter of this article.

References:

1. Ortman JM, Velkoff VA, Hogan H. An aging nation: the older population in the United States; population estimates and projections. May 2014. http://www.census.gov/prod/2014pubs/p25-1140.pdf. Accessed September 1, 2015.

2. Appelbaum PS, Grisso T. Assessing patients’ capacities to consent to treatment. N Engl J Med. 1988; 319:1635-1638.

3. Appelbaum PS. Assessment of patients’ competence to consent to treatment. N Engl J Med. 2007; 357:1834-1840.

4. Kim SYH, Karlawish JHT, Caine ED. Current state of research on decision-making competence of cognitively impaired elderly persons. Am J Geriatr Psychiatry. 2002;10:151-165.

5. Holzer JC, Gansler DA, Moczynski NP, Folstein MF. Cognitive functions in the informed consent evaluation process: a pilot study. J Am Acad Psychiatry Law. 1997;25:531-540.

6. Christensen K, Haroun A, Schneiderman LJ, Jeste DV. Decision-making capacity for informed consent in the older population. Bull Am Acad Psychiatry Law. 1995;23:353-365.

7. Giampieri M. Communication and informed consent in elderly people. Minerva Anestesiol. 2012; 78:236-242.

8. Stanley B, Guido J, Stanley M, Shortell D. The elderly patient and informed consent. JAMA. 1984;252:1302-1306.

9. McKoy JM, Burhenn PS, Browner IS, et al. Assessing cognitive function and capacity in older adults with cancer. J Natl Compr Cancer Net. 2014;12:138-144.

10. Lachs MS, Pillemer K. Elder abuse. Lancet. 2004;364:1263-1272.

11. Peisah C, Finkel S, Shulman K, et al. The wills of older people: risk factors for undue influence. Int Psychogeriatr. 2009;21:7-15.

12.In re Quinlan, 70 NJ 10, 355 A2d 647 (NJ 1976).

13.Cruzan v Director, Missouri Department of Health, (88-1503), 497 US 261 (1990).

14. Emanuel EJ. A review of the ethical and legal aspects of terminating medical care. Am J Med. 1988;84:291-301.

15. US Department of Health and Human Services. Health Information Privacy. http://www.hhs.gov/ocr/privacy. Accessed September 1, 2015.

16. Budnitz DS, Lovegrove MC, Shehab N, Richards C. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365: 2002-2012.

17. Hines LE, Murphy JE. Potentially harmful drug-drug interactions in the elderly: a review. Am J Geriatr Pharmacother. 2011;9:364-377.

18. Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ. 1997;315:1096-1099.

19. The American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2012;60:616-631.

x